# Pembrolizumab Plus Olaparib in LA-HNSCC

> **NCT05366166** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 45 (actual)

## Conditions studied

- Squamous Cell Carcinoma of Head and Neck

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Olaparib
- **DRUG:** Cisplatin
- **RADIATION:** IMRT (intensity modulated radiation therapy)

## Key facts

- **NCT ID:** NCT05366166
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-09-02
- **Primary completion:** 2027-01-21
- **Final completion:** 2030-11-21
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2026-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05366166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05366166, "Pembrolizumab Plus Olaparib in LA-HNSCC". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT05366166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*